Published in J Clin Oncol on February 01, 2001
Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol (2013) 2.50
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood (2015) 1.81
Intraocular lymphoma: update on diagnosis and management. Cancer Control (2004) 1.62
Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. Neurology (2008) 1.44
Molecular pathology of primary intraocular lymphoma. Trans Am Ophthalmol Soc (2003) 1.40
Primary intraocular lymphoma: a review of the clinical, histopathological and molecular biological features. Graefes Arch Clin Exp Ophthalmol (2004) 1.29
Intraocular lymphoma 2000-2005: results of a retrospective multicentre trial. Graefes Arch Clin Exp Ophthalmol (2005) 1.22
How I treat CNS lymphomas. Blood (2013) 1.20
Primary intraocular lymphoma. Arch Pathol Lab Med (2009) 1.13
Primary intraocular lymphoma of T-cell type: report of a case and review of the literature. Graefes Arch Clin Exp Ophthalmol (2004) 1.12
Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment. Leuk Lymphoma (2008) 1.09
Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Clin Cancer Res (2012) 1.07
High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma. Neuro Oncol (2010) 1.03
Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases. Haematologica (2012) 0.98
Progress in central nervous system lymphomas. Br J Haematol (2014) 0.96
Regression of refractory intraocular large B-cell lymphoma with lenalidomide monotherapy. J Clin Oncol (2011) 0.95
Diagnosis and management of primary intraocular lymphoma: an update. Clin Ophthalmol (2007) 0.92
A successful treatment of relapsed primary CNS lymphoma patient with intraventricular rituximab followed by high-dose chemotherapy with autologous stem cell rescue. Yonsei Med J (2009) 0.86
The future of primary intraocular lymphoma (retinal lymphoma). Ocul Immunol Inflamm (2009) 0.84
A novel cytarabine crystalline lipid prodrug: hexadecyloxypropyl cytarabine 3',5'-cyclic monophosphate for proliferative vitreoretinopathy. Mol Vis (2012) 0.81
Chemotherapy in newly diagnosed primary central nervous system lymphoma. Ther Adv Med Oncol (2010) 0.80
Current and emerging pharmacotherapies for primary CNS lymphoma. Clin Med Insights Oncol (2012) 0.80
Efficacy of Procarbazine, Lomustine, and Vincristine Chemotherapy for Recurrent Primary Central Nervous System Lymphomas. Brain Tumor Res Treat (2015) 0.78
High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma-a randomized phase III trial (MATRix). BMC Cancer (2016) 0.78
Treatment of HIV-related primary central nervous system lymphoma with AZT high dose, HAART, interleukin-2 and foscarnet in three patients. Eur J Med Res (2011) 0.78
The Challenge of Primary Central Nervous System Lymphoma. Hematol Oncol Clin North Am (2016) 0.77
Low-dose whole brain radiotherapy with tumor bed boost after methotrexate-based chemotherapy for primary central nervous system lymphoma. Cancer Res Treat (2014) 0.77
Reply to M.C. Chamberlain. J Clin Oncol (2014) 0.75
Treatment of primary intraocular lymphoma with oral trofosfamide: report of two cases and review of the literature. Graefes Arch Clin Exp Ophthalmol (2004) 0.75
New approaches in primary central nervous system lymphoma. Chin Clin Oncol (2015) 0.75
High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study. Bone Marrow Transplant (2017) 0.75
A Comprehensive Assessment of Toxicities in Patients with Central Nervous System Lymphoma Undergoing Autologous Stem Cell Transplantation Using Thiotepa, Busulfan, and Cyclophosphamide Conditioning. Biol Blood Marrow Transplant (2016) 0.75
Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry (2004) 10.58
Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med (1996) 8.57
Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature (1993) 6.67
The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet (1996) 6.43
LEF-1, a gene encoding a lymphoid-specific protein with an HMG domain, regulates T-cell receptor alpha enhancer function [corrected]. Genes Dev (1991) 5.95
Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain (2001) 5.04
Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med (1991) 4.17
Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet (2005) 3.77
Retinal-specific guanylate cyclase gene mutations in Leber's congenital amaurosis. Nat Genet (1996) 3.51
Treatment of older patients with mantle-cell lymphoma. N Engl J Med (2012) 3.46
Limbic encephalitis and small cell lung cancer. Clinical and immunological features. Brain (1997) 2.64
Radiation-induced dementia in patients cured of brain metastases. Neurology (1989) 2.59
All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2. Neurology (2010) 2.53
Leber congenital amaurosis. Mol Genet Metab (1999) 2.52
Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome. Neurology (2007) 2.52
Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann Oncol (2001) 2.39
IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology (2010) 2.36
Glioblastomas with an oligodendroglial component: a pathological and molecular study. J Neuropathol Exp Neurol (2001) 2.24
Long-term clinical outcome of paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology (2000) 2.17
Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites. Genes Chromosomes Cancer (1998) 2.09
The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer (2005) 2.09
Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol (2003) 2.01
Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol (2004) 1.97
Spectrum of ABCR gene mutations in autosomal recessive macular dystrophies. Eur J Hum Genet (1998) 1.97
Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations. Hum Mol Genet (1999) 1.96
Characteristics of respondents and non-respondents to a mailed questionnaire. Am J Public Health (1980) 1.94
Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. Ann Neurol (1999) 1.91
Use of permanent hair dyes and cancer among registered nurses. Lancet (1979) 1.89
Periorbital and orbital cellulitis before and after the advent of Haemophilus influenzae type B vaccination. Ophthalmology (2000) 1.86
Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol (2010) 1.85
A gene for Usher syndrome type I (USH1A) maps to chromosome 14q. Genomics (1992) 1.85
Cloning and functional characterization of early B-cell factor, a regulator of lymphocyte-specific gene expression. Genes Dev (1993) 1.84
Polymerase chain reaction analysis of aqueous humour samples in necrotising retinitis. Br J Ophthalmol (2003) 1.79
Quantitative trait loci: a meta-analysis. Genetics (2000) 1.74
Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology (1996) 1.74
Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain (1997) 1.73
Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med (1995) 1.67
A gene for Stargardt's disease (fundus flavimaculatus) maps to the short arm of chromosome 1. Nat Genet (1993) 1.64
Species relative abundance and direction of introgression in oaks. Mol Ecol (2009) 1.64
Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis (2005) 1.59
Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry (2000) 1.59
Neurological complications of radiotherapy and chemotherapy. J Neurol (1998) 1.56
Supratentorial low-grade gliomas in older patients. Neurology (2009) 1.55
PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia (2008) 1.55
A gene for X-linked idiopathic congenital nystagmus (NYS1) maps to chromosome Xp11.4-p11.3. Am J Hum Genet (1999) 1.54
Primary breast lymphoma. Leuk Lymphoma (2003) 1.50
Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology (2009) 1.48
Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. J Clin Oncol (1995) 1.48
Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies. Neurology (1992) 1.47
Brainstem gliomas in adults: prognostic factors and classification. Brain (2001) 1.46
Fatal necrotizing encephalopathy complicating treatment of malignant gliomas with intra-arterial BCNU and irradiation: a pathological study. J Neurooncol (1989) 1.45
Spectrum of retGC1 mutations in Leber's congenital amaurosis. Eur J Hum Genet (2000) 1.44
The morcellator knife: a new laparoscopic instrument for supracervical hysterectomy and morcellation. Obstet Gynecol (2000) 1.44
Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol (2000) 1.43
Chronic severe uveitis: etiology and visual outcome in 927 patients from a single center. Medicine (Baltimore) (2001) 1.43
[Long-term effects of splenectomy for immune thrombopenic purpura related to human immunodeficiency virus. A retrospective study from 2 groups, with and without splenectomy]. Presse Med (1992) 1.41
Primary follicular lymphoma of the gastrointestinal tract: a study of 25 cases and a literature review. Ann Oncol (2003) 1.40
Carcinoma cell leukemia. Blood (1996) 1.40
Ocular and central nervous system lymphoma: clinical features and diagnosis. Ocul Immunol Inflamm (2000) 1.39
Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry (1996) 1.39
Lack of association between human leukocyte antigens and the anti-Hu syndrome in patients with small-cell lung cancer. Neurology (1998) 1.39
Dose-escalation study of single dose mitoxantrone in combination with timed sequential chemotherapy in patients with refractory or relapsing acute myelogenous leukemia. Leuk Res (2000) 1.39
[Chronic meningitis before diagnosis of celiac disease]. Rev Neurol (Paris) (2002) 1.39
Diagnosis and treatment of cytomegalovirus iridocyclitis without retinal necrosis. Br J Ophthalmol (2006) 1.39
Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med (2001) 1.38
Blindness in a strict vegan. N Engl J Med (2000) 1.38
Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res (1999) 1.38
Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours. Br J Cancer (2009) 1.37
Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. Cancer (1995) 1.36
Early menopause and the risk of myocardial infarction. Am J Obstet Gynecol (1981) 1.36
Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders. J Clin Oncol (2001) 1.35
Screening for germ-line mutations in the NF2 gene. Genes Chromosomes Cancer (1995) 1.35
Outcome of Budd-Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting. Hepatology (1999) 1.35
Neurological complications of primary Sjögren's syndrome. J Neurol (2001) 1.34
A newly identified locus for Usher syndrome type I, USH1E, maps to chromosome 21q21. Hum Mol Genet (1997) 1.34
Radiographic findings in 37 cases of primary CNS lymphoma in immunocompetent patients. Eur Radiol (2001) 1.34
Initial chemotherapy in gliomatosis cerebri. Neurology (2004) 1.33
Oral contraceptive use in relation to nonfatal myocardial infarction. Am J Epidemiol (1980) 1.32
Bitumen morphologies by phase-detection atomic force microscopy. J Microsc (2006) 1.29
Targeting mutants of PTEN reveal distinct subsets of tumour suppressor functions. Biochem J (2001) 1.29
Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res (2000) 1.27
Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings. Leukemia (2012) 1.23
Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann Oncol (2005) 1.22
Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet (1987) 1.22
Necrotising retinopathies simulating acute retinal necrosis syndrome. Br J Ophthalmol (2005) 1.22
Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study. Leukemia (2007) 1.22
JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms. Oncogene (2011) 1.21
A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression. Leukemia (2013) 1.21
Stem cell transplantation in a patient with late-onset nemaline myopathy and gammopathy. Neurology (2008) 1.20